GRACEcast Lung Cancer Audio: Recent Episodes
cancerGRACE - H. Jack West, MD
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.
Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
Dr. David Gerber, University of Texas-Southwestern, discusses results of two important trials of maintenance therapy in advanced NSCLC, including the PRONOUNCE trial and POINTBREAK trials.
Dr. David Gerber, University of Texas-Southwestern, reviews a Swiss study comparing tri-modality therapy with chemoradiation followed by surgery to chemo followed by surgery for stage IIIA NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews results from RTOG 0617 that help clarify the optimal dose of radiation for stage III unresectable NSCLC.
Dr. David Gerber, University of Texas-Southwestern, reviews the current questions in managing locally advanced NSCLC with chemo/radiation as introduction to key issues addressed in trials from ASCO 2013.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI reviews the impact, causes, common symptoms, and approach to staging of small cell lung cancer.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews data supporting a method to define prognosis in early stage non-small cell lung cancer (NSCLC) based on molecular signatures and proposes a new staging system.
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, reviews early efforts in molecularly-defined staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Johannes Kratz, surgeon at Massachusetts General Hospital, explains the potential utility of molecularly guided staging of patients with early stage non-small cell lung cancer (NSCLC).
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for continuation maintenance therapy with Alimta (Pemetrexed) in advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 immunotherapy that has emerged as one of the most promising new developments in lung cancer from 2012.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advanced NSCLC that harbors an ALK or ROS1 rearrangement.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, focusing in this first part on the evolution of techniques to improve staging of lung cancer.
Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by EGFR inhibitors or chest radiation.
Dr. Gerard Silvestri, pulmonologist from Medical University of South Carolina (MUSC) in Charleston, reviews the subject of pneumonitis (inflamation of the lung tissue) induced by chemotherapy commonly used for treating lung cancer.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.
Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer.
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).
Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).
Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.
Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.
Drs. Ramaswamy Govindan from Washington University and Julie Brahmer from Johns Hopkins University answer questions about the current evidence and emerging research on immune-based treatments for lung cancer.
Dr. Julie Brahmer reviews science and early trial results for immunotherapies for lung cancer ranging from cancer vaccines to anti-cancer viruses.
Dr. Ramaswamy Govindan provides a summary of the science behind several promising immunotherapies for lung cancer and the clinical trials that could lead to them being integrated into our treatment plans.
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
Panel discussion with 4 expert thought leaders in lung cancer about how we might best approach testing clinically relevant molecular targets in lung cancer patients.
Panel discussion with 4 expert thought leaders in lung cancer about the prevalence of critical molecular markers in different clinical and histologic groups of lung cancer patients.
Dr. Alice Shaw from Massachusetts General Hospital reviews the frequency of molecular markers in lung cancer by patient sex, smoking status, race, and histology.
Dr. Charles Rudin from Johns Hopkins covers the work from the Lung Cancer Mutation Consortium that identified a wide range of molecular markers in patients with lung adenocarcinoma.
Q and A session with Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, about highlights in lung cancer in 2011.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, here describing evidence supporting lung cancer screening by chest CT, as well as evidence on how best to treat elderly patients with advanced lung cancer.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, with this podcast focusing on ALK rearrangements and new molecular targets in lung cancer.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
Dr. Mark Millard, Pulmonologist at Baylor University, describes how to approach smoking cessation and a range of tools for helping smokers who are motivated to quit.
Dr. Mark Millard, Pulmonologist at Baylor University, reviews the history of tobacco in North America, early research leading to the association of tobacco with lung cancer, and a discussion of how lung cancer prevalence follows patterns of tobacco use.
Case-based discussion with multiple lung cancer experts on optimal treatment of a patient with advanced lung adenocarcinoma, EGFR mutation, & now acquired resistance to EGFR TKI after very good prior response.
Dr. David Yankelevitz, Professor of Radiology at Mount Sinai Medical Center in New York City, reviews technical advances in CT screening for lung nodules, features suggesting whether a nodule is benign or malignant, and the CT-guided biopsy procedure.
Drs. Ben Solomon (Peter MacCallum Cancer Center in Melbourne) and Ross Camidge (Univ. of Colorado) answer Qs on ALK rearrangements and crizotinib (XALKORI) for advanced non-small cell lung cancer (NSCLC).
Dr. Ross Camidge reviews considerations of who to screen for an ALK rearrangement and additional treatment alternatives for patients with ALK-positive advanced non-small cell lung cancer.
Dr. Ben Solomon of Peter MacCallum Cancer Centre in Melbourne Australia reviews ALK Inhibition from mechanism of action to activity and side effect profile of crizotinib, newly approved for patients with ALK-positive advanced non-small cell lung cancer.
Dr. Rogerio Lilenbaum, lung cancer expert, medical oncologist, & Chairman of Cleveland Clinic Florida, answers questions on special management considerations for elderly and frail patients with lung cancer.
Dr. Rogerio Lilenbaum, medical oncologist and Chair of Heme/Onc at Cleveland Clinic in Weston, FL, reviews evidence on how age and other medical problems should be incorporated into management of lung cancer.
Dr. Mario Lacouture, expert dermatologist at Memorial Sloan-Kettering Cancer Center in NYC, answers questions on management of side effects related to skin, hair, and nails for patients on cancer treatments that cause dermatologic complications.
Case-based discussion with multiple lung cancer experts on the controversial question of whether to recommend consolidation chemotherapy after concurrent chemotherapy and radiation for locally advanced NSCLC.
Question and answer session with Drs. Mary Pinder-Schenck from Moffitt Cancer Center in Tampa and Nasser Hanna from Indiana University about highlights in lung cancer from ASCO 2011 annual meeting.
Dr. Nasser Hanna from Indiana University Cancer Center reviews highlights of presentations on advanced/metastatic NSCLC from the ASCO 2011 annual meeting.
Dr. Mary Pinder-Schenck from the H. Lee Moffitt Cancer Center in Tampa, FL reviews highlights of presentations on small cell lung cancer, early stage non-small cell lung cancer, and mesothelioma from the ASCO 2011 meeting.
Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.
Case-based discussion with multiple lung cancer experts on whether to recommend post-operative (adjuvant) chemotherapy for a patient with a less than 4 cm non-small cell lung cancer (NSCLC) tumor with some high risk features.
Case-based discussion with multiple lung cancer experts on whether to recommend post-operative (adjuvant) chemotherapy for a patient with small non-small cell lung cancer (NSCLC) tumor with satellite lesions.
Question and answer session with Dr. Minesh Mehta, Professor of Radiation Oncology at Northwestern University, on topics related to treatments for brain metastases and related complications, especially in the setting of lung cancer.
Dr. Minesh Mehta, Professor of Radiation Oncology at Northwestern University, describes benefits and risks of multiple interventions that are currently used or being studied to reduce risk of developing brain metastases or treat established metastases.
Dr. Lecia Sequist of Massachusetts General Hospital answers questions about acquired resistance to EGFR tyrosine kinase inhibitors and repeat biopsies of tumors over the course of treatment for advanced NSCLC.
Dr. Lecia Sequist of Massachusetts General Hospital describes the results of their experience in repeating biopsies in patients over the course of their ongoing treatment for advanced NSCLC and the changes in tumor characteristics over time.
Dr. Lecia Sequist of Massachusetts General Hospital presents a summary of the challenge of acquired resistance to EGFR tyrosine kinase inhibitors like Tarceva (erlotinib) and Iressa (gefitinib), along with emerging ideas for overcoming it.
Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.
Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for an ex-smoker with a lung adenocarcinoma.
Case discussion with Drs. Tom Hensing of in Chicago and David Jackman in Boston, discussing practical issues around molecular marker testing and recommended treatments for first line and maintenance therapy for a patient with advanced squamous cell NSCLC.
Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, reviewing concerns about risks of aggressive treatment of bulky locally advanced NSCLC and potential management strategies.
Case discussion with Drs. George Blumenschein of MD Anderson and Walter Curran of Emory University, covering management approaches for a stage IIIB locally advanced NSCLC with ambiguous imaging results after chemo and radiation were completed.
Case discussion with Drs. George Blumenschein of MD Anderson Cancer Center and Walter Curran of Emory University, reviewing management options for the range of treatment approaches for patients with stage IIIA N2, locally advanced NSCLC.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.
Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing current evidence and challenges of post-operative treatments for early stage NSCLC in elderly and/or frail patients.
Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, answers questions about what treatments to recommend after first line therapy for advanced NSCLC and when they should be pursued.
Dr. Mark Socinski, medical oncologist and leader of the Thoracic Oncology Program at Univ. of North Carolina, summarizes the evidence and presents a current approach to managing treatment of advanced NSCLC after first line therapy.
Dr. Howard (Jack) West, medical oncologist, President & CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).
Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, discusses questions about individualizing therapy choices for patients with advanced NSCLC.
Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.
Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.
Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of man with an isolated brain metastasis being considered for curative therapy.
Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.
Q&A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.
Case discussion with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute, on a case of a relatively fit man with malignant pleural mesothelioma.
Dr. D. Ross Camidge, medical oncologist at the University of Colorado, provides an overview of the newly identified ALK gene rearrangements, novel therapy to target this, and the promise of molecular oncology.
Case discussion of management options for an elderly man with slowly progressing BAC, with Dr. Anne Tsao of medical oncology at MD Anderson, and Dr. Alex Farivar of thoracic surgery at Swedish Cancer Institute.
Dr. Kristin Manning, expert radiologist at Seattle Radiology, discusses work on lung cancer screening, the features of a pulmonary nodule that raise and lower suspicion for lung cancer, and other aspects of initial and follow-up imaging for lung cancer.
Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses new approaches in molecular profiling of lung cancers.
Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.
Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the neuroendocrine spectrum of lung tumors and the evolving views on bronchioloalveolar carcinoma (BAC).
Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the basic subtypes of non-small cell lung cancer (NSCLC), methods of interpreting NSCLC histology, and the changing importance of pathology in NSCLC management.
Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on first line chemo standards and the transition to maintenance therapy.
Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on never-smokers and EGFR mutation testing.
This slide presentation by Dr. Julie Brahmer, medical oncologist and lung cancer expert at Johns Hopkins University, reviews the factors to be considered in the selection of agents and timing of treatments given after first line therapy for advanced NSCLC.
This slide presentation by Dr. George Simon, Director of Thoracic Oncology at Fox Chase Cancer Center, describes emerging molecular variables that are being studied to optimize individualized selection of systemic treatments for NSCLC.
This slide presentation by Dr. Alan Sandler, medical oncologist and Division Chief of Hematology/Oncology at Oregon Health and Science University, provides an introduction to our current first line treatment options for metastatic NSCLC.
This slide presentation by Dr. Ramiswamy Govindan, medical oncologist at Washington University in St. Louis, offers a broad perspective on the history of treating cancer with chemotherapy, our current treatment approaches, and a preview of emerging technologies that are poised to become a more individualized way of treating cancer.
This slide presentation by Dr. Shirish Gadgeel, medical oncologist at Wayne State University, discusses the considerations and evidence about whether locally advanced (Stage III) NSCLC should be managed surgically or with chemo/radiation alone.
This slide presentation by Dr. Quynh Le, radiation oncologist at Stanford University, describes the emerging new radiation tecnhologies for treating localized NSCLC, particularly stereotactic body radiation therapy (SBRT).
This slide presentation by Dr. Heather Wakelee, medical oncologist at Stanford University, describes the current evidence supporting post-operative treatment of resected non-small cell lung cancer (NSCLC) and leading trials in the field.
This slide presentation by Dr. Ralph Aye, thoracic surgeon and Chief of the Thoracic Oncology Division at Swedish Cancer Institute in Seattle, provides a general introduction to surgical management options for early stage non-small cell lung cancer.
This slide presentation by Dr. Gerard Silvestri, pulmonologist at Medical Univ. of South Carolina, covers the key methods of evaluating a new lung cancer, including initial diagnosis and staging studies.
This slide presentation by Dr. Heather Wakelee, medical oncologist at Stanford University, describes the key clinical research issues being addressed in post-operative treatment of resected non-small cell lung cancer (NSCLC).
This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he covers the optimal treatment strategies for locally advanced (stage III), unresectable NSCLC.
Dr. George Simon, medical oncologist at Fox Chase Cancer Center in Philadelphia, discusses the current evidence and emerging treatment patterns related to molecular variables in treatment of NSCLC.
This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses the evidence supporting the current standard of adjuvant (post-operative) chemotherapy to improve survival for patients with early stage, resected NSCLC.
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West covers the most common management strategies for stage IIIA N2 node-positive NSCLC, with a particular focus on a comparison of preoperative treatment followed by surgery vs. chemo and radiation without surgery.
This interview by medical oncologist Dr. Jack West of Dr. Sarita Dubey, medical oncologist at UCSF Cancer Center, covers the evidence and ongoing questions about the role of chemotherapy in early stage NSCLC.
This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses current and investigational treatment options for relapsed small cell lung cancer, with a particular focus on amrubicin.
This interview by medical oncologist Dr. Jack West of Dr. Suresh Ramalingam, medical oncologist at Emory University in Atlanta, covers the evolving first line treatment standards of chemotherapy and targeted therapy for the first line treatment, as well as the emerging issue of maintenance therapy after initial treatment of advanced NSCLC.
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West presents a general background on the distinct demographic, pathologic, molecular, and treatment outcome features seen among never-smokers with lung cancer.
This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the emerging data about the controversial aspects of timing the transition from first line to second line chemotherapy for advanced non-small cell lung cancer (NSCLC).
This interview by medical oncologist Dr. Jack West of lung cancer expert Dr. Suresh Ramalingam from Winship Cancer Institute at Emory University reviews recent results and the changing perspective on optimal treatment of stage III, locally advanced non-small cell lung cancer (NSCLC).
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the development of current standards and anticipated benefits vs. risks of second line chemotherapy for advanced non-small cell lung cancer (NSCLC).
This interview by medical oncologist Dr. Jack West of lung cancer expert Toni Wozniak from Karmanos Cancer Institute at Wayne State University covers current standards for optimal management of small cell lung cancer (SCLC).
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the unique clinical, imaging, and treatment response features of advanced bronchioloalveolar carcinoma (BAC), a distinct sybtype of lung adenocarcinoma.
This interview by medical oncologist Dr. Jack West of expert thoracic surgeon Eric Vallières covers the basics of the pre-operative work-up and surgical approaches for early stage non-small cell lung cancer (NSCLC).
This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.
This presentation by medical oncologist and lung cancer expert Dr. Jack West introduces the concept of angiogenesis, with a focus on the combination of Avastin (bevacizumab) with chemotherapy for advanced non-small cell lung cancer (NSCLC).
This interview by medical oncologist Dr. Jack West of fellow medical oncologist and lung cancer expert Dr. Janessa Laskin covers the current standards and controversial aspects of post-operative chemotherapy for resected early stage NSCLC.
This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).
This presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.